If we don't the "science will win" folks will be wrong because hiv was the in for getting quicker label expansion for other indications. But instead of moving on from covid on a hunch that more pokes = better results, we couldn't let it go and focus on other indications we have more promise in. Now longhaulers competition is catching up, without a BTD we would be years away from nash or mtnbc and low on cash.

Without great news, a partner or BTD, it could end up being like most other biotech penny stocks. If that happens I don't blame mgmt for their poor decisions, I would only blame myself for being greedy when i had ample chance to hit the sell button at nine or ten bucks but i drank the kool aid. (Pigs get slaughtered they say)

Not calling a loss right now, but tomorrows call better be pretty darn good.